Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We observed suggestive associations with the diabetes risk variant rs7961581 (p = 0.038; between TSPAN8 and LGR5) and rs5215 (p = 0.043; KCNJ11), the LDL risk variant rs11206510 (p = 0.045; PCSK9), as well as the AF risk locus ZFHX3.
|
24135527 |
2013 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Loci that encode targets of emerging LDL-C lowering drugs do not associate with dysglycemia, and this provides provisional evidence that new LDL-C lowering drugs (such as PCSK9 inhibitors) may not influence risk of diabetes.
|
26946290 |
2016 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We investigated the effect of PCSK9-InsLEU polymorphism on the incidence of prediabetes and diabetes.
|
26687699 |
2016 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level.
|
27959767 |
2016 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The standardized prevalence rates of DM in FHBL1 were similar to those of the reference population, with a prevalence rate of 8.2 and 9.2%, respectively, while FHBL2 showed a 4.9% prevalence of DM.
|
27804036 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we assess the available evidence for the association of PCSK9 status with the incidence and control of DM in preclinical and clinical studies, and identify molecular mechanisms regulating PCSK9 expression in the diabetic state.
|
28111330 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
PCSK9 inhibition with evolocumab significantly reduced cardiovascular risk in patients with and without diabetes.
|
28927706 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The coadministration of alirocumab, a PCSK9 inhibitor for treatment of hypercholesterolaemia, and insulin in diabetes mellitus (DM) requires further study.
|
28347654 |
2017 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We studied the effects of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab on fasting plasma glucose, glycated hemoglobin, weight, and new-onset diabetes mellitus.
|
28844508 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The ECDP writing committee judged that these new data did not warrant changes to the decision pathways and algorithms regarding the use of ezetimibe or PCSK9 inhibitors in primary prevention patients with LDL-C <190 mg/dL with or without diabetes mellitus or patients without ASCVD and LDL-C ≥190 mg/dL not due to secondary causes.
|
28886926 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariable Cox regression analysis showed that the third versus the first tertile of PCSK9 (hazard ratio: 1.640; 95% confidence interval: 1.117 to 2.407; p = 0.012), female sex, age, diabetes, smoking, heart failure, previous cerebrovascular and cardiac events, digoxin use, and total cholesterol to high-density lipoprotein cholesterol ratio were associated with CVEs.
|
28911508 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
We sought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes and related biomarkers to gauge the likely effects of PCSK9 inhibitors on diabetes risk.
|
27908689 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
There is an emerging role for the recently developed proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in diabetes, as these agents further reduce serum cholesterol and clinical cardiovascular events beyond the maximum tolerated statin therapy.
|
28871349 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
This sub-analysis of the ODYSSEY COMBO II study compared the effects of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in high cardiovascular risk patients with or without diabetes mellitus (DM) receiving maximally tolerated statin therapy.
|
28206704 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies to PCSK9, given every 2-4 weeks by subcutaneous injection, have been shown to reduce LDL-cholesterol by 50-60% compared with placebo in individuals with and without diabetes.
|
28025677 |
2017 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Plasma PCSK9 levels were measured in 195 people with T1D (mean age 38.8 years, mean diabetes duration 17.2 years, mean glycated haemoglobin [HbA1c] 8.3%), who were free of any lipid-lowering agent.
|
27804190 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggest that sex could modify the effects of obesity and diabetes on PCSK9 in young adults.
|
28093849 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Like mutations with loss of function in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, inhibitors of PCSK9 (PCSK9i) may potentially favor the manifestation of diabetes.
|
29180351 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis.
|
29377473 |
2018 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This post-hoc analysis evaluated efficacy and safety of the PCSK9 inhibitor alirocumab among 984 individuals with DM and ASCVD pooled from 9 ODYSSEY Phase 3 trials.
|
29802688 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate the safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab according to diabetes mellitus status.
|
30183102 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the clinical trials of ezetimibe and PCSK9 inhibitors have not shown an increased DM risk, possibly suggesting that other potential non-well-defined "off-target effects" of hypolipidemic drugs may affect carbohydrate homeostasis.
|
29409336 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite strong indications from genetic studies that PCSK9 inhibition should increase diabetes risk, no such effect has been observed in clinical trials, and in-vitro and in-vivo studies do not clarify this issue.
|
30199407 |
2018 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A lifetime Markov Model was designed to estimate healthcare costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) for PCSK9 inhibition added to standard therapy in patients with Familial Hypercholesterolemia (FH), patients with vascular disease at high MACE recurrence risk, and patients with vascular disease with diabetes mellitus.
|
29306457 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
PCSK9-targeted siRNA-driven strategies may provide a novel therapeutic option for managing dyslipidemia in the presence and absence of diabetes.
|
30487231 |
2019 |